The Value Composite Two of Champions Oncology, Inc. (NasdaqCM:CSBR) is 78. The VC2 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, price to earnings and shareholder yield.  Similarly, the Value Composite One (VC1) is a method that investors use to determine a company’s value.  The VC1 of Champions Oncology, Inc. (NasdaqCM:CSBR) is 76.  A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company.  The VC1 is calculated using the same metrics as VC2, but without taking into consideration shareholder yield.

At times, investors may be prone to making impulsive or irrational decisions when it comes to the stock market. Finding a way to leave emotions out of important investing decisions can greatly assist the investor in achieving their goals. Investors who stay committed to a plan may be able to fight off emotional urges when certain situations arise. Investors may find it useful to rebalance the portfolio as opposed to chasing market performance when adjustments need to be made. Making sure the stock portfolio is aligned to suit the goals of the individual investor may play an important role in being able to consistently sustain profits well into the future.

At the time of writing, Champions Oncology, Inc. (NasdaqCM:CSBR) has a Piotroski F-Score of 6. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

Watching some historical volatility numbers on shares of Champions Oncology, Inc. (NasdaqCM:CSBR), we can see that the 12 month volatility is presently 96.910700. The 6 month volatility is 96.307200, and the 3 month is spotted at 79.950300. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period. 

Shifting gears, we can see that Champions Oncology, Inc. (NasdaqCM:CSBR) has a Q.i. Value of 56.00000. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be.

Champions Oncology, Inc. (NasdaqCM:CSBR) has a current MF Rank of 12294. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks. Champions Oncology, Inc. has a current ERP5 Rank of 15816. The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.

Champions Oncology, Inc. has an M-score Beneish of -3.108963. This M-score model was developed by Messod Beneish in order to detect manipulation of financial statements. The score uses a combination of eight different variables. The specifics of the variables and formula can be found in the Beneish paper “The Detection of Earnings Manipulation”.

Investors may be interested in viewing the Gross Margin score on shares of Champions Oncology, Inc. (NasdaqCM:CSBR). The name currently has a score of 5.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative.

We can now take a quick look at some historical stock price index data. Champions Oncology, Inc. (NasdaqCM:CSBR) presently has a 10 month price index of 1.42857. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 2.08845, the 24 month is 3.02061, and the 36 month is 2.32877. Narrowing in a bit closer, the 5 month price index is 0.67514, the 3 month is 0.86735, and the 1 month is currently 0.83909.

Individual investors often have a lot to deal with when surveying the stock market landscape. Choosing stocks based on recent performance may not work out as well as planned. Stocks that were winners last year, last month, or even last week, may not be winners next week, next month, or next year. Digging into the fundamentals can help the investor see what stocks are set up for future success. Taking multiple approaches when viewing a certain security may help the investor put the puzzle together and see the bigger picture. Staying current on economic data can also help the investor obtain a broader sense of what is driving present market conditions.